IMM 1.49% 34.0¢ immutep limited

Ann: Prima unveils Phase I combination study of IMP321, page-4

  1. 15,518 Posts.
    lightbulb Created with Sketch. 43
    Good stuff!

    It's only a Phase 1 study, so dosing and safety will be the key focus. In itself, that's not likely to have a significant impact, as efficacy is the big brass ring. That will come later.

    A fairly quick trial process, only 26 weeks from start to finish for the patient group. I shouldn't think it will be difficult to recruit Melanoma patients in Qld. Should see trial endpoint result by 4th Qtr 2016.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.